January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline Four Icon Pipeline Four Header  

Cambridge Healthtech Institute’s 2nd Annual
CHO Cell Culture
Enhancing Expression, Performance and Process
January 20-21, 2016

Advances in CHO cell culture technology continue to significantly improve biotherapeutic production. This achievement is due to progress in engineering stable and transient cell lines, enhancing cell culture conditions and performance, as well as optimizing process development. When all are accomplished, higher-production titers and better product quality result. The CHO Cell Culture conference gathers cell line engineers, cell culture specialists and bioprocess development managers to explore the latest data, tools and strategies for improving protein expression, production and product quality.

Final Agenda

Day 1 | Day 2 | Download Brochure


1:00 pm Conference Registration


2:00 Chairperson’s Remarks

Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.

⊲ Featured Presentation
2:05 Multi-Omics Approach for Comparative Studies of Monoclonal Antibody-Producing CHO Cells

Lars_NielsenLars Keld Nielsen, Ph.D., Chair & Professor, Biological Engineering, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland

The availability of the CHO genome has renewed interest in using systems biology to guide rational strain design. Using optimized extraction, RNAseq and SWATH protocols for CHO, we here compared low- and high-producer clones from a single transfection pool. CVs of less than 5% were achieved for full biological triplicates and 55% of all identified proteins were differentially expressed. Targets for increased mAb production were identified and validated.

2:35 Designing CHO Cell Factories Using System Biology Models

Nathan_LewisNathan E. Lewis, Ph.D., Assistant Professor, Department of Pediatrics, University of California, San Diego

Cell line selection and development is becoming increasingly important for controlling critical quality attributes of recombinant therapeutic proteins. To guide the rational engineering of CHO cell lines, we are developing computational models of cell processes that influence product quality and using these models for data interpretation and predictive modeling, thus enabling the development of enhanced protein production hosts.

3:05 High-Throughput Stable Cell Line Platform

Sarah_RueSarah Rue, Ph.D., Senior Research Investigator, Genomics Institute of the Novartis Research Foundation

We have developed methods to establish antibody-expressing stable cell lines in a fully automated and high-throughput platform. This platform is integrated with GNF’s Protein Expression and Purification Platform (PEPP). This workstream is combined with different downstream expression workflows to enable fit-for-purpose use.

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:30 Speed-to-Clinic Cell Line Development without Compromising on Cell Line Stability

Gang_ChenGang Chen, Ph.D., Executive Director, Protein Expression Sciences, Regeneron Pharmaceuticals, Inc.

A key component of Regeneron’s rapid response platform for emerging infectious diseases is our speed-to-clinic cell line technology. Manufacturing-ready cell lines producing antibody-drug candidates are constructed in as short as 18 days. These speed-to-clinic cell lines have several design features that ensure exceptional genetic stability in the absence of prior single-cell cloning and stability screen. The quality attributes of the speed-to-clinic cell lines will be presented.

5:00 Strategies for Optimal Scale-Up and Scale-Down of Cell Culture Bioprocess for Recombinant Protein Production

Kartik_SubramanianKartik Subramanian, Ph.D., Group Leader, Cell Culture, Manufacturing Sciences, AbbVie Bioresearch Center, AbbVie

In this presentation, technical issues relevant to developing representative scale-down models and methodologies for scale-up will be discussed.


5:45 BuzZ Session B

Join your peers and colleagues for interactive roundtable discussions.

6:30-7:30 Reception in the Exhibit Hall with Poster Viewing


Day 1 | Day 2 | Download Brochure


7:45 am Morning Coffee


8:15 Chairperson’s Opening Remarks

Denise Krawitz, Ph.D., Senior Manager, Analytical Operations, Genentech, Inc.


8:20 Product Quality Controls through Process- and Non-Process-Related Strategies

Zhimei_DuZhimei Du, Ph.D., Principal Scientist, Cell Culture Development & Manufacturing, Teva Pharmaceuticals USA

N-linked glycosylation of monoclonal antibody is a critical quality attribute and the existence of the heterogeneous glyco-forms is a common scenario due to the incomplete glycosylation process inside the cell. This presentation reviews the molecular mechanisms and impacts of mAb glycosylation heterogeneity both in vitro and in vivo. Additionally, progress to date in controlling mAb glycosylation by optimizing manufacturing process and the novel non-processrelated approaches will be discussed.

9:00 Protein Expression Profiling of Different CHO Cell Lines: Striking Similarities

Denise Krawitz, Ph.D., Senior Manager, Analytical Operations, Genentech, Inc.

Host cell proteins (HCP) are a complex process-related impurity often monitored with multi-analyte immunoassays like ELISA. In order to use platform ELISAs to monitor HCPs in multiple products, we must demonstrate that the HCP population does not vary significantly with cell culture changes. Proteomics studies of different cell lines grown under different culture conditions suggest that the vast majority of proteins expressed are the same between cell lines.

9:30 Metabolomics for Optimizing CHO Cell Culture Conditions

Zhongqi_ZhangZhongqi Zhang, Ph.D., Scientific Director, Amgen, Inc.

A metabolomics platform was developed for metabolic profiling of complex raw materials, cell culture media and cell lysates. Data were used for the optimization of cell culture media for maximal product productivity and quality. For example, metabolic profiling of soy hydrolysate, a complex medium raw material, revealed several components as productivity markers, among which ornithine was found to promote cell growth and increase productivity.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

11:00 Exploiting the Proteomics Revolution in Biotechnology: From Disease and Antibody Targets to Optimizing Bioprocess Development

Deniz_Baycin-HizalDeniz Baycin Hizal, Ph.D., Scientist II, Antibody Discovery & Protein Engineering, MedImmune

Recent advancements and applications of mass spectrophotometer-based proteomics are enriching biopharmaceutical research and development across multiple fields including target and biomarker discovery, understanding the mechanism of action of drugs, and bioprocess improvements. Quantitative proteomics approaches have been applied to enhance our understanding of recombinant protein production, increase cell growth, delay apoptosis and guide media formulation improvements.

Essential Pharmaceuitcals11:30 A Novel Lipid Supplement Significantly Increases mAb Titer in Bioreactors, without Creating a Deleterious Metabolic Profile or Increasing Biomass

Elhofy_Adam_smallAdam Elhofy, Ph.D., CSO, Essential Pharmaceuticals

A novel lipid supplement, Cell-Ess, creates a more robust animal free and chemically defined system (CD). Cell-Ess has been used to supplement to CD systems in bioreactors resulting in increased titers ranging from 20%-40% without significantly increasing the VCD. Increased productivity resulted in several improved characteristics for bio-production including no significant changes in metabolites or increased biomass including cell debris and host proteins. Protein quality was maintained in samples with increased titers.

12:00 pm Session Break

12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Ice Cream Break in the Exhibit Hall with Poster Viewing


2:00 Chairperson’s Remarks

Lynette Buck, Senior Associate Scientist, Amgen, Inc.

2:05 New Workflow Platform for High-Throughput Cell Line Development

Christian_BenderChristian Bender, Ph.D., Computational Biologist, Antibody Lead Discovery, Bayer HealthCare

We present a new workflow system automating the Cell Line Development process for mammalian cells used to produce therapeutic antibodies and proteins. It tracks clones produced and screened in high-throughput mode, collects relevant characterization data and streamlines high-throughput workflows by interfacing with automation equipment and bioreactors. We show how Bayer’s Global Biologics groups use it and present applications of the generation of GMP-ready cell lines and their transfer into process development.

2:35 Epigenetic Marks Enable Rejection of Unstable Chinese Hamster Ovary Cell Lines

Ulrich_GoepfertUlrich Goepfert, Ph.D., Principal Scientist, Cell Line & Molecular Development, Roche Innovation Center Penzberg

During expansion and maintenance, CHO cell lines are prone to production instability, which may be caused by promoter silencing, loss of transgene copies or posttranscriptional effects. Silencing of recombinant genes may be accompanied by DNA methylation and histone modification. We examined a variety of epigenetic modifications and identified molecular indicators which provide the opportunity to enrich stable producers.

3:05 Next Level of E. coli Expression - Higher Yields and Better Quality

David Vikström, Ph.D., CTO, Xbrane Bioscience

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing

4:15 Comparison of ExpiCHO and Expi293 Expression Systems: Considerations for Transient Protein Production

Nina_JainNina Jain, Research Associate, Alexion Pharmaceuticals

We compare Thermo Fisher Scientific’s high-density transient transfection systems, Expi293 and ExpiCHO. We discuss the expression and characterization of multiple proteins (mAbs, Fabs, bispecifics and fusion proteins) generated in both systems. We also compare the proteins expressed in these systems to reference standards generated in stable production cell lines and discuss the implications this data has for system selection.

4:45 A High-Yielding CHO Transient System: Coexpression of Genes Encoding EBNA-1 and GS Enhances Transient Protein Expression

Olalekan Daramola, Ph.D., Cell Sciences, Biopharmaceutical Development, MedImmune

5:00 A High Cell Density Transient Transfection System for Therapeutic Protein Expression Based on a CHO GS-Knockout Cell Line

Gavin_BarnardGavin Barnard, Ph.D., Group Leader, Eli Lilly and Company

We discuss the development of a PEI-mediated transient CHO expression system capable of generating high titers, scalable up to 6L. This was achieved through rigorous optimization of cell density, DNA and PEI concentrations followed by process development strategies. The system was further improved by the co-expression of a specific transcription factor (XBP1S). This platform enables rapid expression of therapeutic protein candidates, thus alleviating one bottleneck in the drug development process.

5:15 Molecule Assessment and CLD for mAb Candidate Selection

Lynette Buck, Senior Associate Scientist, Amgen, Inc.

Molecule Assessment is the consideration of manufacturing, stability and product attributes when designing/selecting protein candidates for commercialization. This is done at the Cell Line Development stage not only to facilitate meeting First in Human needs but also to ensure productivity needs to meet future commercial demands.

6:00-7:00 Reception in the Tiki Pavilion

7:00 Close of Conference

Day 1 | Day 2 | Download Brochure